Cover Image


Japan Generics Market Analysis

出版商 RNCOS E-Services Pvt. Ltd. 商品編碼 231240
出版日期 內容資訊 英文 55 Pages
Back to Top
日本的學名藥市場分析 Japan Generics Market Analysis
出版日期: 2012年02月01日 內容資訊: 英文 55 Pages



第1章 分析師的見解

第2章 分析方法

第3章 近幾年的市場動向

  • 保險藥局與DPC(診斷群各分類綜合評價制度)引進醫院:學名藥的大貢獻
  • 日本市場:對大型醫藥品企業來說學名藥成為新的核心市場
  • 非專利藥品癌症治療藥:急劇成長預測

第4章 人口統計概況

第5章 日本的醫藥品市場預測(到2014年為止)

第6章 日本的學名藥市場概況

  • 醫療費用支出
    • 不同疾病·各年齡層的支出額
  • 學名藥的普及率
  • 學名藥市場預測(到2014年為止)
  • 非專利藥品處方藥和非專利藥品成藥
  • 流通系統
    • 各醫療機關
    • 各銷售管道
  • 近幾年的學名藥的銷售情形

第7章 消費者行動分析

  • 患者方面的意見
  • 醫生·藥劑師方面的意見

第8章 法規環境

  • 衛生署(MHLW)所扮演的角色
  • 學名藥的認證及銷售許可時的主要必要條件
  • 專利制度

第9章 政府的主要促進策略

第10章 市場機會的評估

  • 專利失效
  • 治療治療

第11章 主要企業

  • Nichi-Iko Pharmaceutical
  • 澤井製藥
  • 大洋藥品工業
  • 東和藥品
  • Meiji Seika
  • Nippon Chemipher




Japan is the world's second largest pharmaceutical markets in the world, but due to public perception, the share of generic drugs has remained low in it. However, worried over rising healthcare expenses and high mortality rates, the government has now been playing a vital role in promoting generics. The patent expiry of branded drugs and active ingredients will also act as a strong growth driver for the market in future. According to the findings of our latest report, the generics market in Japan stood at around US$ 9 Billion in 2010. It estimates that the growth in generic drugs will outshine the expansion in overall pharmaceutical market.

According to "Japan Generics Market Analysis", Japan is expected to be the next generic hub, and cancer related generics exhibit vast potential. The report finds out how vital is the role of National Health Insurance (NHI) pharmacies and Diagnosis Procedure Combination (DPC) hospitals in the industry development. It was observed that the DPC hospitals, in particular, have been growing at a robust rate, promoting generics penetration. We also found that ethical generics hold the majority share in the generic drugs market.

A detailed demographic analysis was carried out in the research that revealed that the population aged 65 years and above accounts for maximum healthcare-related expenditures in Japan, and hence becomes the target population for generics promotion. Further, a meticulous disease and age-wise segmentation has provided the holistic understanding of the healthcare-related demand parameters prevailing in the country.

The government in Japan has taken several initiatives to ensure growth and promotion of generics industry in the country. Recently, special premium-based incentives have been given to pharmacists on generic promotion. In near future, the government plans to bring in more reforms in medical care system. Our research talks about such revisions and reforms briefly to present a balanced outlook of the industry to clients. Analysis of current trends, profiles of key players in the Japanese generic market, and recent developments in the industry have also been included in the comprehensive study.

Table of Contents

1. Analyst View

2. Research Methodology

3. Recent Market Trends

  • 3.1 NHI Pharmacies and DPC Hospitals to Contribute Majorly in Generics
  • 3.2 Japan: Next Generic Hub for Pharma Majors
  • 3.3 Cancer Generics Projected for Exorbitant Growth

4. Demographics Profile

5. The Japanese Pharmaceutical Market Outlook to 2014

6. The Japanese Generic Drugs Market Overview

  • 6.1 Healthcare Expenditure
  • 6.1.1 Expenditure by Disease and Age Group
  • 6.2 Generics Penetration
  • 6.3 Generics Market Outlook to 2014
  • 6.4 Ethical vs OTC Generics
  • 6.5 Distribution System
  • 6.5.1 By Medical Institution
  • 6.5.2 By Distribution Channel
  • 6.6 Recent Generic Launches

7. Consumer Behavior Analysis

  • 7.1 Patients View
  • 7.2 Physicians and Pharmacist View

8. Regulatory Environment

  • 8.1 Role of MHLW
  • 8.2 Key Requirements for Generics Approval and Marketing Authorization
  • 8.3 Patent System

9. Key Government Initiatives

10. Opportunity Assessment

  • 10.1 By Patent Expiration
  • 10.2 By Therapeutic Treatment

11. Key Players

  • 11.1 Nichi-Iko
  • 11.2 Sawai Pharmaceuticals
  • 11.3 Taiyo Pharmaceutical
  • 11.4 Towa
  • 11.5 Meiji Seika
  • 11.6 Nippon Chemipher

List of Figures:

  • Figure 3-1: Cancer Mortality Rate (per 100,000 Population), 2000 & 2010
  • Figure 5-1: Pharmaceutical Market (Billion US$), 2010-2014
  • Figure 5-2: Share of Generics in Pharmaceutical Market (2011)
  • Figure 5-3: Pharmaceutical Sales by Facility (%), 2009
  • Figure 6-1: Healthcare Expenditure (Billion US$), 2010 & 2015
  • Figure 6-2: Percentage Distribution of Healthcare Expenditure by Diseases for Population Aged below 65 (2008)
  • Figure 6-3: Percentage Distribution of Healthcare Expenditure by Diseases for Population Aged 65 and Above (2008)
  • Figure 6-4: Share of Generic Drugs in Pharmaceuticals Market w.r.t Developed Countries (2009)
  • Figure 6-5: Generic Drugs Market (Billion US$), 2010-2014
  • Figure 6-6: Market Share of Generic Drugs Manufacturers (2010)
  • Figure 6-7: Generic Drugs Market by Segment (%), 2009
  • Figure 6-8: Generic Drugs Market by Medical Institution (%), 2008 & 2009
  • Figure 6-9: Number of DPC Hospitals (FY 2007 to FY 2010)
  • Figure 6-10: Generic Drugs Market by Distribution Channel (%), 2008 & 2009
  • Figure 11-1: Sawai Pharmaceutical - Sales by Therapeutic Category (%), FY 2010
  • Figure 11-2: Towa Pharmaceutical - Sales by Therapeutic Category (%), Mar 2011

List of Tables:

  • Table 3-1: Recent Industry Activities in Cancer Generics
  • Table 4-1: Demographic Characteristics (2010 & 2015)
  • Table 6-1: Recent Generic Drugs Launch of Key Players (2011)
  • Table 8-1: Application Fee for Manufacturing and Marketing of Generics (JPY)
  • Table 9-1: Key Measures for Generic Drugs Promotion
  • Table 10-1: Patent Expiry of Key Drugs in Japan (2012-2015)
Back to Top